Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.74 |
| ▸ | CA12 | O43570 | 4/20 | 0.64 |
| ▸ | CA1 | P00915 | 4/20 | 0.64 |
| ▸ | CA2 | P00918 | 4/20 | 0.64 |
| ▸ | CA9 | Q16790 | 4/20 | 0.64 |
| ▸ | PKM | P14618 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | IDE | P14735 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.57 |
| ▸ | HLCS | P50747 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.56 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17208802 | 1.00 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL17933958 | 1.00 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL6034966 | 1.00 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL7820513 | 0.97 | TDP1 (0.76) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL288457 | 0.95 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL9733492 | 0.95 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL13049579 | 0.95 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL10308271 | 0.95 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL20483620 | 0.95 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL13065003 | 0.95 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-10307422-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | USHER III INITIATIVE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180207159-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | BIOFOCUS DPI LTD. (GB) | 2018-07-26 | — | — | US | disclosed |
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-9925187-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | USHER III INITIATIVE, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170143718-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | BIOFOCUS DPI LTD. (GB) | 2017-05-25 | — | — | US | disclosed |
| US-9549910-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | USHER III INITIATIVE, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160158172-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE, INC. | 2016-06-09 | — | — | US | disclosed |
| US-9260381-B2 | Pyrazolopyridazines and methods for treating retinal degenerative diseases and hearing loss associated with usher syndrome | USHER III INITIATIVE, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150266812-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9079909-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome | USHER III INITIATIVE, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20130252936-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE (US) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266812-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, PDE6B | TDP1 214/4885CA12 4595/4885CA1 4578/4885 |
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | PSMG3, HSPA5, TTR | TDP1 1328/4885CA12 3185/4885CA1 2538/4885 |
| US-20180207159-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, NR2E3 | TDP1 203/4885CA12 4570/4885CA1 4544/4885 |
| US-10307422-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | ALDH1A2, ALDH1A3, NR2E3 | TDP1 203/4885CA12 4570/4885CA1 4544/4885 |
| US-20170143718-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, NR2E3 | TDP1 203/4885CA12 4570/4885CA1 4544/4885 |
| US-20130252936-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, NR2E3 | TDP1 203/4885CA12 4570/4885CA1 4544/4885 |
| US-20160158172-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, NR2E3 | TDP1 203/4885CA12 4570/4885CA1 4544/4885 |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | TNF, HLA-DRB1, GSTK1 | TDP1 1010/4885CA12 511/4885CA1 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.